Phase 3 trial of Biogen and UCB's dapirolizumab pegol shows significant improvement in lupus disease activity. Read more here ...

01 优时比和渤健公布了3期PHOENYCS GO研究的详细结果，显示dapirolizumab pegol与标准治疗联用显著改善中度至重度系统性红斑狼疮患者的疾病活动程度。 今日，优时比（UCB）和渤健（Biogen）公布了3期PHOENYCS ...

We recently compiled a list of the 10 Best Genomics Stocks To Buy Right Now. In this article, we are going to take a look at ...

After the unexpected success of their PHOENYCS GO study for dapirolizumab pegol in lupus earlier this fall, Biogen and UCB ...

Needham downgraded Biogen Inc (NASDAQ:BIIB), citing limited catalysts for the company over the next year. Alzheimer’s drug ...

Needham has downgraded Biogen (NASDAQ:BIIB) to hold from buy, citing a lack of near-term catalysts and slow uptake for the ...

We recently published a list of 10 Cheap NASDAQ Stocks To Invest In Now. In this article, we are going to take a look at ...

A slow launch for Alzheimer's medicine Leqembi, a lackluster pipeline and a challenging drug launch environment are just a ...

Biogen (NASDAQ:BIIB – Free Report) had its price target boosted by Robert W. Baird from $294.00 to $300.00 in a research ...

周三，花旗开始对Biogen (NASDAQ:BIIB)股票进行覆盖，给予中性评级，并设定190美元的目标价。这一新的覆盖反映了对这家生物技术公司财务前景的谨慎态度，主要是由于其传统业务面临压力。 Biogen的核心产品，包括用于多发性硬化症(MS)、脊髓性肌萎缩症(SMA)的治疗以及来自抗CD20疗法的特许权使用费，年复合增长率(CAGR)分别下降了12%、3%和2%。为了应对这些下降，公司致力 ...

Biogen’s stock rose 1% Thursday, after Europe’s pharmaceutical regulator issued a positive opinion on the Alzheimer’s disease ...

UCB and Biogen (BIIB) presented detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol, or DZP, a novel Fc-free anti-CD40L drug candidate, demonstrating significant ...